Albuterol Inhaler |
Proventil HFA; Proventil Inhaler; Ventolin Inhaler |
Clinical Trial: Genetic Determinants of the Bronchodilatation Effect of Albuterol Ex-Vivo.
This study is currently recruiting patients.
Verified by Hadassah Medical Organization August 2004
|
Purpose
The role played by ß2AR polymorphisms in determining the bronchial response to ß2AR agonist drugs, has been confirmed by several studies.
The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and drug responsiveness. An ex-vivo model (organ bath technique) will be used to investigate association between polymorphisms in the coding region of ß2AR and the response of bronchial rings derived from human lung tissue to the respective agonists (i.e. salbutamol).
In the second part of the study the same bronchial rings will be incubated for 24 hours in a solution containing fixed concentration of albuterol. A second dose response curve for rising concentrations of albuterol will be constructed and a relationship between β2 genetic polymorphisms and the extent of desensitization to albuterol will be investigated.
In addition, through specifically designed receptor binding assay the bronchial tissue will be used to define the affinity (Kd) and expression (Vmax) of the ß2 receptor. These data will enable to enhance our understanding regarding the mechanism responsible for the association noted between ß2AR polymorphism and altered drug effect.
| Condition | Intervention |
|---|---|
| Asthma | Drug: albuterol |
MedlinePlus related topics: Asthma
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Official Title: The Effect of β2 Genetic Polymorphisms on the Brochodilatation Effect of Albuterol Ex-Vivo.
Expected Total Enrollment: 150
Study start: August 2003
Eligibility
Inclusion Criteria:
- Macroscopically normal pulmonary tissue
Exclusion Criteria:
- The presence of pthological finding in the pulmonary tissue
Location and Contact Information
Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il
Israel
Hadassah Medical Organization, Jerusalem, Israel; Recruiting
Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il
Yoseph Caraco, MD, Principal Investigator
Yoseph Caraco, ND, Principal Investigator, Hadassah Medical Organization
More Information
Last Updated: September 12, 2005
Record first received: September 11, 2005
ClinicalTrials.gov Identifier: NCT00162422
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Albuterol Inhaler (Drug Digest)
- Proventil HFA (Drug Digest)

Not Signed In -

